Aclarion, Inc. (ACON) is a globally renowned company that operates in the technology sector. Its main area of focus is the development, innovation and retail of new-generation technological solutions. The company is located in the US, but it operates worldwide, serving thousands of customers across the globe. The company has a highly experienced team of professionals who work tirelessly towards providing clients with innovative and top-quality products and solutions.
Aclarion Inc. is held in high esteem for its uncompromised quality, reliability, and dedication to innovation. Over the years, it has built a robust reputation in the market as a dependable and innovative technology solutions provider. It caters to both individual clients and organizations, offering products and solutions that seek to propel IT infrastructure and operations to a level that matches the rapidly evolving digital landscape.
The company's product line echoes its commitment to quality and innovation. This line ranges from home-based technological solutions, mobile devices, computer systems, networking and IoT devices, to software applications tailored to meet the variable needs of clients. Driven by research and development, Aclarion Inc. dedicates significant resources to better understand the changing needs of the market and to develop solutions that stand the test of time.
Aside from offering world-class products, Aclarion, Inc. stands out due to its strong customer service culture. The company believes in not just selling products, but going the extra mile to ensure a comprehensive customer experience. As such, it provides round-the-clock customer support, ready to assist clients with any issues arising from the use of its products, and it also offers guidance on how users can get optimal performance from the company's solutions.
Aclarion, Inc. continued success lies in its ability to anticipate, meet and exceed market demands. It continually adapts to changes in the market through constant innovation, and in doing so ensures that it stays ahead of its competition.
Aclarion's mission is to create a technologically advanced world where everyone has access to reliable and efficient solutions. In its journey towards achieving this mission, the company has made significant strides, breaking ground in areas such as advanced computing, networking, Internet of Things (IoT), and mobile technology.
In conclusion, Aclarion, Inc. is a shining beacon in the global technology landscape. Its dedication to quality, innovation, and exceptional customer service has placed it in a league of its own in the global Tech industry. Aclarion, Inc. is a brand synonymous with advancement, quality, and reliability, and it continues to shape the future of technology with its innovative solutions.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Aclarion, Inc. announced the University of Arizona College of Medicine – Phoenix has joined its CLARITY trial as a new clinical site, bringing the total to ten active enrollment locations. The CLARITY study aims to prove the clinical and economic value of Nociscan, a technology leveraging MR Spectroscopy and AI to identify sources of chronic low back pain. This expansion is expected to bolster evidence for Nociscan as a standard of care for surgical decision-making in chronic low back pain, with initial interim results anticipated in Q4 2026.
Aclarion has added the University of Arizona College of Medicine – Phoenix as a new clinical site for its CLARITY trial, which aims to demonstrate the effectiveness of its Nociscan technology in improving surgical outcomes for chronic low back pain. The University of Arizona's strong neurosurgery and orthopedic spine program, with its expertise in complex spine surgery and commitment to research, makes it a valuable addition to the study. Nociscan uses MR Spectroscopy and AI to identify the precise disc responsible for a patient's pain, with an initial internal data readout anticipated in Q4 2026.
Aclarion director Amanda Williams purchased 5,857 shares of common stock for $15,989 on August 17, 2026. This transaction increased her direct holdings to 25,857 shares, with the stock showing a 12% gain recently despite a year-to-date decline. The company has also been expanding its Nociscan diagnostic platform and rejected a $4 per share acquisition bid, stating it undervalued the company.
Aclarion director William Wesemann recently purchased 2,150 shares of the company's common stock for $5,031. This insider buy comes as ACON trades significantly down year-to-date and near its 52-week low. The company, despite being unprofitable, holds more cash than debt and has a strong current ratio.
Aclarion has received a Notice of Allowance for a U.S. Patent application titled "Multi-Voxel Prescription for Lumbar Disc Evaluation," which aims to enhance the accuracy and adoption of its Nociscan MR Spectroscopy (MRS) scan process. This patent protects the precise capture of MRS data within the target disc, reducing scan time, simplifying technologist training, and improving reproducibility. The innovation is designed to improve data reliability and streamline the acquisition workflow for Nociscan, a SaaS platform that helps physicians distinguish between painful and nonpainful discs in the lumbar spine, extending Aclarion's intellectual property to over 65 issued and pending patents worldwide.